• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Oct 4 - CVM Reorganization


<



This sounds about right and something needs to happen. There is way too much management out there. From RBD to the lower-level DM management. Probably too many office-based reps too. Hopefully no one will lose their job and any change will be “headcount neutral”. It’s most likely rumor though. I doubt that anything is happening any time soon.
 




Its what we've known is coming forever.

What ever is left of the Actelion/rare disease team will be rolled up into Janssen cardiology.

ASM job be eliminated & rolled into TM role (comp already was) and DM's redistributed. RBD's & Lisa will land somewhere in the org.

The PAH experiment failed. It was a $30B gamble that will be lucky to get 50% return.

NOTHING that they talked about after the aquisition came to be.

No new indications. No new products. No new devices. No patent extentions. Opsumit has a 18 months left with generics already handing us our asses & Uptravi is a niche drug with limited use. QD formulation 12 months out & then you can close the book on it too.

Jnj tried jumping into the rare disease market. In the end- they grossly over-paid for an amazing company & the destroyed it by trying to wring out every dime they could. Chased off all of the talent while killing a brand that once chapioned the disease state.
 
















It has been posted before. All Pharma lays off around the Holidays. The 2 conference calls are yet to come. You just don't want to be on the first one.

Relax. Nothing you can do.

It is in the Pharma God's hands.
 








Similar threads

Replies
37
Views
7K
Janssen
anonymous
Replies
141
Views
34K
Janssen
anonymous
Replies
1
Views
839
Janssen
Anonymous
Replies
1
Views
232